DermaSensor raised $16 million in Series B funding, bringing the total raised to $43 million - fueling the expansion of its FDA cleared, handheld skin cancer detection device.

Published in the Journal of Primary Care and Community Health, the joint FDA pivotal studies demonstrated the performance and benefits of the hand-held, non-invasive, optical spectroscopy device in point-of-care skin lesion evaluation.

Simplifying Skin Cancer Detection.